Back to Clinical Trials

Clinical Trials: Urology


Source: Pfizer
The objective of this study is to determine the problems and questions of safety and efficacy of Toviaz® under the standard conditions of usage. Read More
Last Updated: 29 Sep 2015
Source: Predictive Biosciences
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine Read More
Last Updated: 06 Jun 2011
Source: Ferring Pharmaceuticals
The rationale of the study was to evaluate different degarelix dosing regimens for a three-month interval that was to produce and maintain castration in prostate cancer patients through immediate and prolonged testosterone suppression, and to provide confirmatory evidence of the safety of degarelix. Read More
Last Updated: 11 Nov 2010
Source: Spectrum Pharmaceuticals, Inc
The purpose of this study is to evaluate the recurrence rate of noninvasive bladder cancer at 2 years in patients with tumor histology Ta, G1-G2 who are randomized to receive TUR-BT plus EOquin® versus those who are randomized to receive TUR-BT plus placebo. Read More
Last Updated: 25 May 2015
Source: Dendreon
The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases. Read More
Last Updated: 08 Jan 2017
Source: Ferring Pharmaceuticals
The purpose of this study was to see if giving Degarelix every month for 7 months then stop treatment for 7 months (intermittent therapy) would show a reduction of negative effects of androgen deprivation therapy by increasing the quality of life while keeping prostate specific antigen (PSA) levels suppressed. Read More
Last Updated: 20 Oct 2016
Source: AEterna Zentaris
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect safety and efficacy data for this dosage regimen of cetrorelix pamoate. For this study, study medication (Cetrorelix pamoate) is administered by injection in the ... Read More
Last Updated: 31 Mar 2011
Source: GTx
The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN). Read More
Last Updated: 30 Jan 2013
Source: Ferring Pharmaceuticals
The purpose of this trial was to find an optimal dose for a new trial drug - degarelix (FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was studied. Patients participating were treated with FE200486 on one occasion. Thereafter they came in for visits following a specific schedule until blood samples showed that there was no further effect. Read More
Last Updated: 17 May 2011
Source: GTx
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer. However, one of the side effects is bone loss or thinning of the bones that can lead to osteoporosis and an increased risk of bone fractures (breaking of the bones). The purpose of the study is to determine whether or not the addition of toremifene citrate (the study ... Read More
Last Updated: 12 Nov 2013
Source: Boston Scientific Corporation
This post-marketing study is being conducted to evaluate the long-term safety and effectiveness of the Prolieve Thermodilatation® System (Prolieve®) in the treatment of Benign Prostatic Hyperplasia (BPH). A secondary objective is to assess the safety and effectiveness of re-treatment with Prolieve® and determine the percent of subjects electing to be re-treated with Prolieve® rather than alternate therapy. This study will follow subjects treated with ... Read More
Last Updated: 03 Feb 2013
Source: Novartis
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies. Read More
Last Updated: 22 Jan 2008
Source: Ferring Pharmaceuticals
This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years (including one year in the main study). Read More
Last Updated: 11 Mar 2015
Source: PRAECIS Pharmaceuticals Inc.
Praecis is currently conducting a 2000 patient Experience Study; this is a Phase IV commitment postmarketing safety study in the Food and Drug Administration (FDA) indicated population of patients receiving Plenaxis®. The purpose of the study is to estimate the incidence of immediate-onset systemic allergic reactions in the indicated population receiving Plenaxis® and to determine whether the hazard rate changes over time. Read More
Last Updated: 17 Sep 2006
Source: GP-Pharm
The purpose of this study is to look at the efficacy and safety of leuprolide acetate in patients with prostate cancer. Read More
Last Updated: 11 Nov 2007
Source: Predictive Biosciences
The purpose of the study is to evaluate subjects with gross or microscopic hematuria undergoing scheduled cystoscopy to determine the absence or presence of bladder cancer. Read More
Last Updated: 06 Jun 2011
Source: Astellas Pharma Inc
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy. This study will also assess the effect of 12 weeks of treatment with solifenacin succinate versus placebo on quality of life (QOL) as measured by questionnaires. Read More
Last Updated: 05 Oct 2014
Source: Ferring Pharmaceuticals
The purpose of this study is to investigate the efficacy and safety of several doses of the melt formulation of desmopressin in a broad population of adult patients with nocturia. Read More
Last Updated: 28 Sep 2015
Source: Spectrum Pharmaceuticals, Inc
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL diluent), post transurethral resection-bladder tumor (TURBT). Following Central Pathology review of histology and Double Blind Phase qualification, patients with confirmed eligibility will be randomized to receive either 6 weekly ... Read More
Last Updated: 11 Dec 2016
Source: Ferring Pharmaceuticals
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer. Read More
Last Updated: 01 May 2014
Page 1 of 50